Full Breakdown
Trump Administration’s “Most-Favored Nation” Drug-Pricing Push and Its Ripple Effects in Canada
By Drooid · · How we work
Core Policy Announcement
In September, President Donald Trump announced a nationwide effort to lower prescription-drug costs for U.S. patients by requiring manufacturers to match the lowest prices paid in a set of “reference” nations. The “most-favoured nation” (MFN) policy ties Medicaid and Medicare deals to benchmarks drawn from 19 affluent countries, including Canada. “We went from paying the highest drug prices in the world to paying the lowest drug prices in the world,” the president said.
Scope and Mechanics
- Companies involved: Agreements have been secured with 26 large drug makers, such as Pfizer and Eli Lilly, after letters were sent to 17 major manufacturers demanding price cuts.
- Reference framework: Prices are to be aligned with those in the 19 designated reference countries.
- Deal structure: Public Citizen obtained copies of the agreements, noting extensive redactions and carve-outs that exempt certain GLP-1 weight-loss drugs (e.g., Zepbound) from MFN pricing.
Expert and Industry Perspectives
Potential Canadian Impact
“For Canadians waiting for a new cancer therapy, a rare disease treatment, or first-in-class medicine, these aren’t abstract policy debates,” warned Innovative Medicines Canada.
Mina Tadrous, associate professor at the University of Toronto, cautioned that manufacturers may seek higher prices abroad, reduce discounts, or postpone launches to offset lost U.S. revenue. “The huge asterisks around all of this is like are we [Canada] actually the lowest prices? … we don’t know what the impacts are going to be on Canadians.”
Family physician Nav Persaud of St. Michael’s Hospital observed that many patients already sacrifice medications due to cost, a situation that could worsen if Canadian prices rise.
Policy Rationale
Dr. Thomas Hwang of Brigham and Women’s Hospital explained that MFN pricing aims to bring U.S. drug costs in line with those of similarly sized, wealthy nations.
Data & Statistics
Conflicting Reports & Gaps
The publicly released agreements are heavily redacted, leaving key financial terms undisclosed. Critics note the GLP-1 carve-out as evidence of selective application.
Official Statements & Responses
The White House frames MFN pricing as a “big shift” intended to bring U.S. drug prices from the world’s highest to a level comparable with other wealthy nations.
Criticism & Opposition
Canadian industry group Innovative Medicines Canada, physicians, and academic experts argue that the MFN approach could lead to higher Canadian drug prices, delayed access to new therapies, and broader market uncertainty.
Outlook
The MFN pricing initiative is slated to affect Medicaid and Medicare drug purchases imminently, but its full impact on Canadian drug markets remains uncertain pending the release of complete agreement details. Stakeholders on both sides of the border are watching for evidence of price adjustments, supply-chain shifts, or delayed drug launches that could reshape access to medicines.